Prostate cancer

Disease ID:790
Name:Prostate cancer
Associated with:9 targets
Database Links
Disease Ontology: DOID:10283
OMIM: 176807

Targets

CXCR5
References:  8
GPR160
Comments:  Gene associated with prostate cancer identified by microarray analysis.
References:  2,5
PKR1
References:  7
Mutations:  PKR1 is associated with 2 mutation. Click here for details
Peroxisome proliferator-activated receptor-γ
Comments:  PPARgamma is expressed in human prostate adenocarcinomas and cell lines derived from human prostate tumors.
References:  6
Androgen receptor
Comments:  Mutations of AR affecting ligand binding as well as gene amplification of AR have been described. Alteration at the receptor level: sometimes increased. Alternative splice variants have been shown to play a role in castration resistant prostate cancer.
References:  1,3-4
TLR1
TLR6
TLR9
regulator of G-protein signaling 8
Role:  RGS8 is one of a number of transcripts identified in the hereditary prostate cancer (HPC1) locus.
References:  9

Ligands

No ligand related data available for Prostate cancer

References

Show »

1. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL et al.. (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med., 371 (11): 1028-38. [PMID:25184630]

2. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. (2007) Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood, 109 (4): 1720-7. [PMID:17068154]

3. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J et al.. (2015) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur. Urol., 67 (1): 53-60. [PMID:24882673]

4. Linja MJ, Visakorpi T. (2004) Alterations of androgen receptor in prostate cancer. J. Steroid Biochem. Mol. Biol., 92 (4): 255-64. [PMID:15663988]

5. Mudipalli A, Owen RD, Preston RJ. (2005) The effect of arsenicals on ultraviolet-radiation-induced growth arrest and related signaling events in human keratinocytes. Int. J. Oncol., 27 (3): 769-78. [PMID:16077927]

6. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. (2000) Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. U.S.A., 97 (20): 10990-5. [PMID:10984506]

7. O'Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS. (2013) The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat. Rev. Cancer, 13 (6): 412-24. [PMID:23640210]

8. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard Jr JW. (2009) Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int. J. Cancer, 125 (10): 2288-95. [PMID:19610059]

9. Sood R, Bonner TI, Makalowska I, Stephan DA, Robbins CM, Connors TD, Morgenbesser SD, Su K, Faruque MU, Pinkett H et al.. (2001) Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus. Genomics, 73 (2): 211-22. [PMID:11318611]